{"paper_id":"7d40b758-0925-4093-be7e-097b1f80af8d","body_text":"Abstract\nCorrespondence to the original research entitled “Effects of ranibizumab and zoledronic acid on endometriosis in a rat model” published by Ozdemir et al.\nReferences\nUreyen Ozdemir E, Adali E, Islimye Taskin M, Yavasoglu A, Aktug H, Oltulu F et al (2021) Effects of ranibizumab and zoledronic acid on endometriosis in a rat model. Arch Gynecol Obstet. https://doi.org/10.1007/s00404-021-06104-9\nFerro Desideri L, Barra F, Ferrero S, Traverso CE, Nicolo M (2019) Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration. Expert Opin Biol Ther 19(8):735–751\nWeinstein O, Abu Tailakh M, Lifshitz T, Novack V, Levy J (2020) Intravitreal bevacizumab treatment for neovascular age-related macular degeneration and thromboembolic events. Eur J Ophthalmol 30(1):66–71\nNicolo M, Morlacchi A, Cappelli F, Ferro Desideri L, Colombo V, Musetti D et al (2020) Real-life data in the treatment of neovascular age-related macular degeneration: results from the imaculaweb registry evaluated in a single italian medical retina center. Ophthalmologica 243(6):453–460\nFerro Desideri L, Cutolo CA, Traverso CE, Nicolo M (2021) Razumab—the role of biosimilars for the treatment of retinal diseases. Drugs Today (Barcelona) 57(8):499–505\nChen HX, Cleck JN (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6(8):465–477\nOryan A, Sahvieh S (2021) Effects of bisphosphonates on osteoporosis: focus on zoledronate. Life Sci 264:118681\nBarra F, Scala C, Mais V, Guerriero S, Ferrero S (2018) Investigational drugs for the treatment of endometriosis, an update on recent developments. Expert Opin Investig Drugs 27(5):445–458\nLa Rosa VL, De Franciscis P, Barra F, Schiattarella A, Torok P, Shah M et al (2020) Quality of life in women with endometriosis: a narrative overview. Minerva Med 111(1):68–78\nFunding\nThis paper is not funded.\nAuthor information\nAuthors and Affiliations\nContributions\nFB: DATA collection and manuscript writing; LFD: Data collection and manuscript writing; SF: manuscript editing; CG: project administration; CET: manuscript editing and revision; MN: project development and manuscript revision.\nCorresponding author\nEthics declarations\nConflict of interest\nFabio Barra, Lorenzo Ferro Desideri, Simone Ferrero, Claudio Gustavino, Carlo Enrico Traverso, and Massimo Nicolò declare that they have no conflict of interest to declare.\nEthical approval\nThis article does not contain any studies with human participants or animals performed by any of the authors.\nAdditional information\nPublisher's Note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nRights and permissions\nAbout this article\nCite this article\nBarra, F., Ferro Desideri, L., Gustavino, C. et al. Concerns on ranibizumab and zoledronic acid safety for experimentally treating women with endometriosis. Arch Gynecol Obstet 306, 569–570 (2022). https://doi.org/10.1007/s00404-021-06390-3\nReceived:\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s00404-021-06390-3","source_license":"CC0","license_restricted":false}